Westfield Capital Management Co. LP Invests $370,000 in Illumina, Inc. (NASDAQ:ILMN)

Westfield Capital Management Co. LP purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, Holdings Channel.com reports. The firm purchased 2,836 shares of the life sciences company’s stock, valued at approximately $370,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ILMN. Freemont Management S.A. purchased a new position in shares of Illumina during the third quarter valued at approximately $1,565,000. Cetera Advisors LLC purchased a new position in Illumina during the 1st quarter worth $610,000. Weybosset Research & Management LLC grew its stake in shares of Illumina by 92.0% in the 3rd quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock worth $2,354,000 after acquiring an additional 8,650 shares in the last quarter. B. Riley Wealth Advisors Inc. raised its holdings in shares of Illumina by 176.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company’s stock valued at $749,000 after purchasing an additional 4,579 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Illumina by 3.6% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 399,966 shares of the life sciences company’s stock valued at $41,748,000 after purchasing an additional 13,725 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ILMN. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a research report on Thursday, October 17th. Daiwa Capital Markets raised Illumina from a “neutral” rating to a “buy” rating and upped their target price for the company from $120.00 to $154.00 in a report on Friday, August 16th. Canaccord Genuity Group lifted their price target on Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday, November 5th. Robert W. Baird upped their price objective on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $156.00 target price on shares of Illumina in a research report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $164.00.

Illumina Trading Up 2.6 %

NASDAQ:ILMN opened at $143.82 on Tuesday. The company has a market cap of $22.81 billion, a P/E ratio of -14.44 and a beta of 1.13. Illumina, Inc. has a 1 year low of $93.51 and a 1 year high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The stock’s fifty day moving average price is $140.90 and its two-hundred day moving average price is $125.17.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm’s revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.33 EPS. As a group, analysts expect that Illumina, Inc. will post 4.11 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.